Alumis shares sink after the biotech reports envudeucitinib missed its primary endpoint in a mid-stage lupus trial.
Barron's reports that California-based Alumis disclosed the failure of its experimental treatment envudeucitinib to meet the primary endpoint in a mid-stage lupus trial. The company's announcement prompted immediate market reaction with its shares declining sharply according to the publication's coverage. The article focuses on the biotech firm's own statement regarding the clinical results and the resulting stock movement. No additional outcomes or next steps from the trial appear in the reported details at this time. The account centers on the direct connection between the trial miss and the observed share price change.
4.2K
1 post, first seen 5d ago
Alumis shares sink after the biotech reports envudeucitinib missed its primary endpoint in a mid-stage lupus trial.
Barron's reports that California-based Alumis disclosed the failure of its experimental treatment envudeucitinib to meet the primary endpoint in a mid-stage lupus trial. The company's announcement prompted immediate market reaction with its shares declining sharply according to the publication's coverage. The article focuses on the biotech firm's own statement regarding the clinical results and the resulting stock movement. No additional outcomes or next steps from the trial appear in the reported details at this time. The account centers on the direct connection between the trial miss and the observed share price change.
Barron's@barronsonlineA Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It https://trib.al/FTCuBWU
Barron's@barronsonlineA Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It https://trib.al/FTCuBWU
